Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CABA NASDAQ:ELUT NASDAQ:HCAQ NASDAQ:MGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCABACabaletta Bio$1.44-5.3%$1.77$0.99▼$6.74$77.13M2.741.15 million shs935,451 shsELUTElutia$2.04+0.5%$1.96$1.61▼$5.12$83.46M0.8825,923 shs15,286 shsHCAQHealthCor Catalio Acquisition$1.03-2.8%$8.72$9.48▼$11.00$21.95MN/A114,974 shs254,632 shsMGXMetagenomi$2.25-2.2%$1.84$1.23▼$4.92$85.98M-0.14925,210 shs317,557 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCABACabaletta Bio-5.26%-13.25%-10.00%+7.46%-79.72%ELUTElutia+0.49%+6.25%-5.56%0.00%-44.11%HCAQHealthCor Catalio Acquisition+3.92%-7.83%+54.20%+53.60%-9.40%MGXMetagenomi-2.17%-7.41%+39.75%+39.75%-42.01%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCABACabaletta Bio1.7951 of 5 stars3.52.00.00.01.10.80.6ELUTElutia3.4514 of 5 stars3.55.00.00.01.93.30.6HCAQHealthCor Catalio AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AMGXMetagenomi2.43 of 5 stars3.54.00.00.00.61.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCABACabaletta Bio 3.00Buy$14.43901.98% UpsideELUTElutia 3.00Buy$8.00292.16% UpsideHCAQHealthCor Catalio Acquisition 0.00N/AN/AN/AMGXMetagenomi 3.00Buy$13.00477.78% UpsideCurrent Analyst Ratings BreakdownLatest HCAQ, MGX, ELUT, and CABA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025CABACabaletta BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.005/16/2025CABACabaletta BioCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.00 ➝ $13.005/15/2025CABACabaletta BioGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$23.00 ➝ $25.005/15/2025MGXMetagenomiChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$13.00 ➝ $12.005/14/2025MGXMetagenomiWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$20.00 ➝ $16.005/9/2025ELUTElutiaLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $8.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCABACabaletta BioN/AN/AN/AN/A$3.12 per shareN/AELUTElutia$24.38M3.44N/AN/A($1.31) per share-1.56HCAQHealthCor Catalio AcquisitionN/AN/AN/AN/AN/AN/AMGXMetagenomi$52.29M1.61N/AN/A$6.28 per share0.36Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCABACabaletta Bio-$115.86M-$2.54N/AN/AN/AN/A-78.29%-65.68%8/6/2025 (Estimated)ELUTElutia-$53.95M-$1.93N/AN/AN/A-168.23%N/A-96.70%8/6/2025 (Estimated)HCAQHealthCor Catalio AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/AMGXMetagenomi-$78.06M-$2.11N/AN/AN/A-172.21%-31.21%-22.21%8/13/2025 (Estimated)Latest HCAQ, MGX, ELUT, and CABA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025CABACabaletta Bio-$0.71N/AN/AN/AN/AN/A8/13/2025Q2 2025MGXMetagenomi-$0.62N/AN/AN/A$7.72 millionN/A5/21/2025Q1 2025CABACabaletta Bio-$0.67-$0.71-$0.04-$0.71N/AN/A5/13/2025Q1 2025MGXMetagenomi-$0.62-$0.68-$0.06-$0.68$8.75 million$4.13 million5/8/2025Q1 2025ELUTElutia-$0.20-$0.21-$0.01-$0.21$6.65 million$6.03 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCABACabaletta BioN/AN/AN/AN/AN/AELUTElutiaN/AN/AN/AN/AN/AHCAQHealthCor Catalio AcquisitionN/AN/AN/AN/AN/AMGXMetagenomiN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCABACabaletta BioN/A3.963.96ELUTElutiaN/A0.810.70HCAQHealthCor Catalio AcquisitionN/A0.480.48MGXMetagenomiN/A5.855.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCABACabaletta BioN/AELUTElutia74.03%HCAQHealthCor Catalio Acquisition84.18%MGXMetagenomiN/AInsider OwnershipCompanyInsider OwnershipCABACabaletta Bio11.25%ELUTElutia27.60%HCAQHealthCor Catalio AcquisitionN/AMGXMetagenomi17.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCABACabaletta Bio5050.74 million45.03 millionOptionableELUTElutia18041.12 million29.77 millionNot OptionableHCAQHealthCor Catalio Acquisition221.31 millionN/ANot OptionableMGXMetagenomi23637.38 million30.73 millionN/AHCAQ, MGX, ELUT, and CABA HeadlinesRecent News About These CompaniesMetagenomi (MGX) Presents Latest in Gene Editing TechnologiesJuly 29, 2025 | msn.comMetagenomi Showcases Advanced AI-Enhanced Gene Editing for Neurological Disorders at ASGCT MeetingJuly 14, 2025 | msn.comMetagenomi (NASDAQ:MGX) Stock Price Up 22% - Still a Buy?July 10, 2025 | marketbeat.comInsider Selling: Metagenomi, Inc. (NASDAQ:MGX) CEO Sells 10,785 Shares of StockJune 10, 2025 | insidertrades.comMetagenomi, Inc. (NASDAQ:MGX) Analysts Are Cutting Their Estimates: Here's What You Need To KnowMay 16, 2025 | finance.yahoo.com2MGX : Demystifying Metagenomi: Insights From 4 Analyst ReviewsMay 15, 2025 | benzinga.comMetagenomi Reports Promising Hemophilia A Study ResultsMay 14, 2025 | tipranks.comMetagenomi, Inc.: Metagenomi Reports Business Updates and First Quarter 2025 Financial ResultsMay 14, 2025 | finanznachrichten.deMetagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025May 14, 2025 | globenewswire.comMetagenomi (MGX) Reports Q1 Loss, Misses Revenue EstimatesMay 13, 2025 | zacks.comMetagenomi Reports Business Updates and First Quarter 2025 Financial ResultsMay 13, 2025 | globenewswire.comMetagenomi to Present at Upcoming Scientific MeetingsMay 2, 2025 | globenewswire.comMetagenomi Leads The Charge With These 3 Penny StocksApril 10, 2025 | uk.finance.yahoo.comMetagenomi price target lowered to $7 from $14 at H.C. WainwrightApril 4, 2025 | markets.businessinsider.comMetagenomi, Inc. Common Stock (MGX) Latest After Hours TradesMarch 31, 2025 | nasdaq.comBiotech stocks slide as Marks resignation seen being negative for sectorMarch 31, 2025 | markets.businessinsider.comBullish: Analysts Just Made A Significant Upgrade To Their Metagenomi, Inc. (NASDAQ:MGX) ForecastsMarch 27, 2025 | uk.finance.yahoo.comMetagenomi, Inc.: Metagenomi Reports Business Updates and Full Year 2024 Financial ResultsMarch 19, 2025 | finanznachrichten.deMetagenomi Faces Legal Battle Over Alleged Misleading Statements in Moderna CollaborationMarch 19, 2025 | tipranks.comMetagenomi, Inc. Reports 2024 Financial Results and Pipeline ProgressMarch 18, 2025 | tipranks.comMetagenomi files $250M mixed securities shelfMarch 18, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHCAQ, MGX, ELUT, and CABA Company DescriptionsCabaletta Bio NASDAQ:CABA$1.44 -0.08 (-5.26%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.48 +0.05 (+3.13%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.Elutia NASDAQ:ELUT$2.04 +0.01 (+0.49%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.04 0.00 (0.00%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.HealthCor Catalio Acquisition NASDAQ:HCAQHealthCor Catalio Acquisition Corp. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2020 and is based in New York, New York.Metagenomi NASDAQ:MGX$2.25 -0.05 (-2.17%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.22 -0.02 (-1.11%) As of 08/1/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
